<DOC>
	<DOC>NCT01455103</DOC>
	<brief_summary>The purpose of this study is to evaluate pharmacodynamic changes of BMS-936559 treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with unresectable Stage III or IV Melanoma.</brief_summary>
	<brief_title>Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Men and women â‰¥ 18 years Eastern Cooperative Oncology Group (ECOG) status = 0 to 1 Subjects with unresectable Stage III or IV Melanoma who are either refractory or intolerant to, or have refused standard therapy for treatment of metastatic Melanoma Subject must have histologic or cytologic confirmation of advanced Melanoma Subjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical risk and must consent to pre and posttreatment biopsies Active or progressing brain metastases Other concomitant malignancies (with some exceptions per protocol) Active or history of autoimmune disease Positive test for human immunodeficiency virus (HIV) 1&amp;2 or known acquired immunodeficiency syndrome (AIDS) History of any hepatitis Prior therapy with any antibody/drug that targets the T cell coregulatory proteins, including but not limited to, anti Programmed cell death 1 (PD1), anti Programmed cell death ligand 1 (antiPDL1), antiPDL2, antiCD137, antiOX40, antiCD40 or anti Cytotoxic T lymphocyteassociated antigen 4 (antiCTLA4) antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>